Dr. Hodi on Nivolumab in Combination With Ipilimumab for Advanced Melanoma

F. Stephen Hodi, MD, director of the Melanoma Treatment Center and director of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute, discusses the results of a trial presented at the 2015 AACR Annual Meeting.

At the meeting, Hodi presented data on a randomized phase II trial looking at nivolumab plus ipilimumab compared with ipilimumab alone for the treatment of patients with advanced melanoma. The combination elicited a significantly higher response rate. Patients receiving the combination had a 22% complete response rate compared with 0% for those receiving ipilimumab alone.

Treatment-related adverse events (AEs) occurred more frequently in the combination arm, but were manageable nonetheless.

<<<

View more from the 2015 AACR Annual Meeting